Clarus Ventures Ii, Llc - Net Worth and Insider Trading

Clarus Ventures Ii, Llc Insider Ownership Reports

Based on ownership reports from SEC filings, as the reporting owner, Clarus Ventures Ii, Llc owns 7 companies in total, including NanoString Technologies Inc (NSTGQ) , Venus Concept Inc (VERO) , and TetraLogic Pharmaceuticals Corp (TLOG) among others .

Click here to see the complete history of Clarus Ventures Ii, Llc’s form 4 insider trades.

Insider Ownership Summary of Clarus Ventures Ii, Llc

Ticker	Comapny	Transaction Date	Type of Owner
NSTGQ	NanoString Technologies Inc	2013-06-25	10 percent owner
VERO	Venus Concept Inc	2017-10-11	10 percent owner
TLOG	TetraLogic Pharmaceuticals Corp	2016-02-08	10 percent owner
		2015-06-24	10 percent owner
		2013-09-25	10 percent owner
		2013-10-25	10 percent owner
		2012-06-04	10 percent owner

Clarus Ventures Ii, Llc Trading Performance

Please note GuruFocus will not track the insiders’ transaction performance if he/she does not have buying transactions.

Clarus Ventures Ii, Llc Ownership Network

Ownership Network List of Clarus Ventures Ii, Llc

No Data

Ownership Network Relation of Clarus Ventures Ii, Llc

Clarus Ventures Ii, Llc Owned Company Details

What does NanoString Technologies Inc do?

Who are the key executives at NanoString Technologies Inc?

Clarus Ventures Ii, Llc is the 10 percent owner of NanoString Technologies Inc. Other key executives at NanoString Technologies Inc include Chief Commercial Officer Jonathan Todd Garland , Chief Financial Officer K Thomas Bailey , and director & President and CEO R Bradley Gray .

NanoString Technologies Inc (NSTGQ) Insider Trades Summary

Over the past 18 months, Clarus Ventures Ii, Llc made no insider transaction in NanoString Technologies Inc (NSTGQ). Other recent insider transactions involving NanoString Technologies Inc (NSTGQ) include a net purchase of 97,661 shares made by R Bradley Gray , a net purchase of 44,161 shares made by K Thomas Bailey , and a net purchase of 35,400 shares made by William Young .

In summary, during the past 3 months, insiders sold 0 shares of NanoString Technologies Inc (NSTGQ) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of NanoString Technologies Inc (NSTGQ) were sold and 201,722 shares were bought by its insiders, resulting in a net purchase of 201,722 shares.

NanoString Technologies Inc (NSTGQ)'s detailed insider trading history can be found in Insider Trading Tracker table.

NanoString Technologies Inc Insider Transactions

No Available Data

What does Venus Concept Inc do?

Who are the key executives at Venus Concept Inc?

Clarus Ventures Ii, Llc is the 10 percent owner of Venus Concept Inc. Other key executives at Venus Concept Inc include President Global Sales Ross Portaro , 10 percent owner Michael Willingham Masters , and director & Chief Executive Officer Silva Rajiv De .

Venus Concept Inc (VERO) Insider Trades Summary

Over the past 18 months, Clarus Ventures Ii, Llc made no insider transaction in Venus Concept Inc (VERO). Other recent insider transactions involving Venus Concept Inc (VERO) include a net sale of 102,859 shares made by Anthony Natale ,

In summary, during the past 3 months, insiders sold 0 shares of Venus Concept Inc (VERO) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 6,857 shares of Venus Concept Inc (VERO) were sold and 0 shares were bought by its insiders, resulting in a net sale of 6,857 shares.

Venus Concept Inc (VERO)'s detailed insider trading history can be found in Insider Trading Tracker table.

Venus Concept Inc Insider Transactions

No Available Data

What does TetraLogic Pharmaceuticals Corp do?

Who are the key executives at TetraLogic Pharmaceuticals Corp?

Clarus Ventures Ii, Llc is the 10 percent owner of TetraLogic Pharmaceuticals Corp. Other key executives at TetraLogic Pharmaceuticals Corp include other: See Remarks Hudson Bay Capital Management Lp , other: See Remarks Lazard Asset Management Llc , and other: See Remarks Nomura Holdings Inc .

TetraLogic Pharmaceuticals Corp (TLOG) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of TetraLogic Pharmaceuticals Corp (TLOG) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of TetraLogic Pharmaceuticals Corp (TLOG) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

TetraLogic Pharmaceuticals Corp (TLOG)'s detailed insider trading history can be found in Insider Trading Tracker table.

TetraLogic Pharmaceuticals Corp Insider Transactions

No Available Data

What does Astria Therapeutics Inc do?

Who are the key executives at Astria Therapeutics Inc?

Clarus Ventures Ii, Llc is the 10 percent owner of Astria Therapeutics Inc. Other key executives at Astria Therapeutics Inc include Chief Medical Officer Christopher Morabito , director & 10 percent owner Perceptive Life Sciences Master Fund Ltd , and Chief Business Officer Andrea Matthews .

Astria Therapeutics Inc (ATXS) Insider Trades Summary

Over the past 18 months, Clarus Ventures Ii, Llc made no insider transaction in Astria Therapeutics Inc (ATXS). Other recent insider transactions involving Astria Therapeutics Inc (ATXS) include a net purchase of 5,204,223 shares made by Perceptive Life Sciences Master Fund Ltd , and a net sale of 20,000 shares made by Christopher Morabito .

In summary, during the past 3 months, insiders sold 10,000 shares of Astria Therapeutics Inc (ATXS) in total and bought 0 shares, with a net sale of 10,000 shares. During the past 18 months, 20,000 shares of Astria Therapeutics Inc (ATXS) were sold and 5,204,223 shares were bought by its insiders, resulting in a net purchase of 5,184,223 shares.

Astria Therapeutics Inc (ATXS)'s detailed insider trading history can be found in Insider Trading Tracker table.

Astria Therapeutics Inc Insider Transactions

No Available Data

What does IVERIC bio Inc do?

Who are the key executives at IVERIC bio Inc?

Clarus Ventures Ii, Llc is the 10 percent owner of IVERIC bio Inc. Other key executives at IVERIC bio Inc include SVP & COO Keith Westby , SVP & CFO and Treasurer David Francis Carroll , and Senior Vice President & CCO Christopher Paul Simms .

IVERIC bio Inc (ISEE) Insider Trades Summary

Over the past 18 months, Clarus Ventures Ii, Llc made no insider transaction in IVERIC bio Inc (ISEE). Other recent insider transactions involving IVERIC bio Inc (ISEE) include a net sale of 243,904 shares made by Keith Westby , a net sale of 128,049 shares made by David Francis Carroll , and a net sale of 19,457 shares made by Glenn Sblendorio .

In summary, during the past 3 months, insiders sold 0 shares of IVERIC bio Inc (ISEE) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 391,410 shares of IVERIC bio Inc (ISEE) were sold and 0 shares were bought by its insiders, resulting in a net sale of 391,410 shares.

IVERIC bio Inc (ISEE)'s detailed insider trading history can be found in Insider Trading Tracker table.

IVERIC bio Inc Insider Transactions

No Available Data

What does Aerie Pharmaceuticals Inc do?

Who are the key executives at Aerie Pharmaceuticals Inc?

Clarus Ventures Ii, Llc is the 10 percent owner of Aerie Pharmaceuticals Inc. Other key executives at Aerie Pharmaceuticals Inc include Chief Financial Officer Peter Frederick Lang , director & Chief Executive Officer Raj Kannan , and Vice President of Finance Jeffrey Calabrese .

Aerie Pharmaceuticals Inc (AERI) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Aerie Pharmaceuticals Inc (AERI) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Aerie Pharmaceuticals Inc (AERI) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Aerie Pharmaceuticals Inc (AERI)'s detailed insider trading history can be found in Insider Trading Tracker table.

Aerie Pharmaceuticals Inc Insider Transactions

No Available Data

What does Achillion Pharmaceuticals Inc do?

Who are the key executives at Achillion Pharmaceuticals Inc?

Clarus Ventures Ii, Llc is the 10 percent owner of Achillion Pharmaceuticals Inc. Other key executives at Achillion Pharmaceuticals Inc include EVP & Chief Commercial Officer Paul E Firuta , EVP & Chief Medical Officer Steven Zelenkofske , and General Counsel Martha E Manning .

Achillion Pharmaceuticals Inc (ACHN) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Achillion Pharmaceuticals Inc (ACHN) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Achillion Pharmaceuticals Inc (ACHN) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Achillion Pharmaceuticals Inc (ACHN)'s detailed insider trading history can be found in Insider Trading Tracker table.

Achillion Pharmaceuticals Inc Insider Transactions

No Available Data

Clarus Ventures Ii, Llc Mailing Address

Above is the net worth, insider trading, and ownership report for Clarus Ventures Ii, Llc. You might contact Clarus Ventures Ii, Llc via mailing address: 101 Main Street, Suite 1210, Cambridge Ma 02142.

Discussions on Clarus Ventures Ii, Llc

No discussions yet.

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us ETF Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.